Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Reviews in Allergy & Immunology
Published in: Clinical Reviews in Allergy & Immunology 2/2017

01-04-2017

The Role of STAT Signaling Pathways in the Pathogenesis of Systemic Lupus Erythematosus

Authors: Aleš Goropevšek, Marija Holcar, Tadej Avčin

Published in: Clinical Reviews in Allergy & Immunology | Issue 2/2017

Login to get access

Abstract

Systemic lupus erythematosus (SLE) is a multisystem autoimmune disorder with a broad spectrum of clinical presentations and association with multiple immunological abnormalities. Recent research of the Janus kinase (JAK)—signal transducer and activator of transcription (STAT) signaling pathway—revealed aberrant STAT signaling in inflammatory conditions and autoimmune diseases including SLE. STAT proteins are major components in interferon (IFN)-dependent gene expression and are responsible for signal transduction of over 50 cytokines, hormones, and growth factors regulating key cellular processes such as survival, proliferation, and differentiation. This review summarizes the present evidence from experimental animal models and patients with SLE for the involvement of STAT pathways in the pathogenesis of SLE underlining the role of different members of the STAT family. Genome-wide association studies provided evidence that variations in STAT4 gene are linked to the development of SLE in humans. First integration with genome-wide epigenomics data suggests that control of CD4+ T cell differentiation in which STATs play a major role may be an important component of the genetic contribution to disease susceptibility. Increased transcript and total protein STAT1 levels were described both in SLE T and B cells suggestive of the priming mechanisms that augment STAT1 signaling responses to IFN. STAT3 has a crucial role in Th17 differentiation, T follicular helper, and B cells, and STAT3 inhibition could represent a possible future therapeutic target in SLE. STAT5B appears to act as a critical modulator of human Treg development and function. While the imbalance between phosphorylated STAT5 and STAT3 in human SLE T cells was implicated in dysregulated IL-10 expression, Treg-specific deletion of STAT3 in mouse model even enhanced Th17-mediated inflammation. Finally, we present also a comprehensive analysis of studies investigating STAT signaling responses in conventional and regulatory subsets of SLE T and B cells and possible implications of STAT inhibition for clinical therapy.
Literature
1.
2.
Parkes M, Cortes A, van Heel DA, Brown MA (2013) Genetic insights into common pathways and complex relationships among immune-mediated diseases. Nat Rev Genet 14:661–673PubMedCrossRef
3.
4.
Rullo OJ, Tsao BP (2013) Recent insights into the genetic basis of systemic lupus erythematosus. Ann Rheum Dis 72(Suppl 2):ii56–ii61PubMedCrossRef
5.
Tak YG, Farnham PJ (2015) Making sense of GWAS: using epigenomics and genome engineering to understand the functional relevance of SNPs in non-coding regions of the human genome. Epigenetics Chromatin 8:57PubMedPubMedCentralCrossRef
6.
Farh KK, Marson A, Zhu J et al (2015) Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature 518:337–343PubMedCrossRef
7.
8.
Miguel-Escalada I, Pasquali L, Ferrer J (2015) Transcriptional enhancers: functional insights and role in human disease. Curr Opin Genet Dev 33:71–76PubMedPubMedCentralCrossRef
9.
Hnisz D, Abraham BJ, Lee TI et al (2013) Super-enhancers in the control of cell identity and disease. Cell 155:934–947PubMedCrossRef
10.
Parker SC, Stitzel ML, Taylor DL et al (2013) Chromatin stretch enhancer states drive cell-specific gene regulation and harbor human disease risk variants. Proc Natl Acad Sci U S A 110:17921–17926PubMedPubMedCentralCrossRef
11.
12.
13.
14.
Levy DE, Darnell JE Jr (2002) Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 3:651–662PubMedCrossRef
15.
16.
17.
18.
Darnell JE Jr, Kerr IM, Stark GR (1994) Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264:1415–1421PubMedCrossRef
19.
20.
21.
22.
Dorritie KA, Redner RL, Johnson DE (2014) STAT transcription factors in normal and cancer stem cells. Adv Biol Regul 56:30–44PubMedCrossRef
23.
Ehret GB, Reichenbach P, Schindler U et al (2001) DNA binding specificity of different STAT proteins. Comparison of in vitro specificity with natural target sites. J Biol Chem 276:6675–6688PubMedCrossRef
24.
Au-Yeung N, Mandhana R, Horvath CM (2013) Transcriptional regulation by STAT1 and STAT2 in the interferon JAK-STAT pathway. Jakstat 2, e23931PubMedPubMedCentral
25.
Abroun S, Saki N, Ahmadvand M, Asghari F, Salari F, Rahim F (2015) STATs: an old story, yet mesmerizing. Cell J 17:395–411PubMedPubMedCentral
26.
Vinkemeier U, Cohen SL, Moarefi I, Chait BT, Kuriyan J, Darnell JE Jr (1996) DNA binding of in vitro activated Stat1 alpha, Stat1 beta and truncated Stat1: interaction between NH2-terminal domains stabilizes binding of two dimers to tandem DNA sites. EMBO J 15:5616–5626PubMedPubMedCentral
27.
28.
Saleiro D, Platanias LC (2015) Intersection of mTOR and STAT signaling in immunity. Trends Immunol 36:21–29PubMedCrossRef
29.
Woo CH, Shishido T, McClain C et al (2008) Extracellular signal-regulated kinase 5 SUMOylation antagonizes shear stress-induced antiinflammatory response and endothelial nitric oxide synthase expression in endothelial cells. Circ Res 102:538–545PubMedCrossRef
30.
31.
O'Shea JJ, Notarangelo LD, Johnston JA, Candotti F (1997) Advances in the understanding of cytokine signal transduction: the role of Jaks and STATs in immunoregulation and the pathogenesis of immunodeficiency. J Clin Immunol 17:431–447PubMedCrossRef
32.
Zhong M, Henriksen MA, Takeuchi K et al (2005) Implications of an antiparallel dimeric structure of nonphosphorylated STAT1 for the activation-inactivation cycle. Proc Natl Acad Sci U S A 102:3966–3971PubMedPubMedCentralCrossRef
33.
Wenta N, Strauss H, Meyer S, Vinkemeier U (2008) Tyrosine phosphorylation regulates the partitioning of STAT1 between different dimer conformations. Proc Natl Acad Sci U S A 105:9238–9243PubMedPubMedCentralCrossRef
34.
Porritt RA, Hertzog PJ (2015) Dynamic control of type I IFN signalling by an integrated network of negative regulators. Trends Immunol 36:150–160PubMedCrossRef
35.
Lui PY, Jin DY, Stevenson NJ (2015) MicroRNA: master controllers of intracellular signaling pathways. Cell Mol Life Sci 72:3531–3542PubMedCrossRef
36.
37.
Bocchini CE, Kasembeli MM, Roh SH, Tweardy DJ (2014) Contribution of chaperones to STAT pathway signaling. Jakstat 3, e970459PubMedPubMedCentral
38.
39.
Ward AC, Touw I, Yoshimura A (2000) The Jak-Stat pathway in normal and perturbed hematopoiesis. Blood 95:19–29PubMed
40.
O'Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A (2015) The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med 66:311–328PubMedCrossRef
41.
Holcar M, Goropevsek A, Ihan A, Avcin T (2015) Age-related differences in percentages of regulatory and effector T lymphocytes and their subsets in healthy individuals and characteristic STAT1/STAT5 signalling response in helper T lymphocytes. J Immunol Res 2015:352934PubMedPubMedCentralCrossRef
42.
Li G, Ju J, Weyand CM, Goronzy JJ (2015) Age-associated failure to adjust type I IFN receptor signaling thresholds after T cell activation. J Immunol 195:865–874PubMedPubMedCentralCrossRef
43.
Raphael I, Nalawade S, Eagar TN, Forsthuber TG (2015) T cell subsets and their signature cytokines in autoimmune and inflammatory diseases. Cytokine 74:5–17PubMedCrossRef
44.
45.
Bonelli M, Shih HY, Hirahara K et al (2014) Helper T cell plasticity: impact of extrinsic and intrinsic signals on transcriptomes and epigenomes. Curr Top Microbiol Immunol 381:279–326PubMedPubMedCentral
46.
47.
Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O'Garra A, Murphy KM (1993) Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 260:547–549PubMedCrossRef
48.
Girdlestone J, Wing M (1996) Autocrine activation by interferon-gamma of STAT factors following T cell activation. Eur J Immunol 26:704–709PubMedCrossRef
49.
Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH (2000) A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 100:655–669PubMedCrossRef
50.
51.
Zheng W, Flavell RA (1997) The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 89:587–596PubMedCrossRef
52.
Park H, Li Z, Yang XO et al (2005) A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 6:1133–1141PubMedPubMedCentralCrossRef
53.
Ivanov II, McKenzie BS, Zhou L et al (2006) The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126:1121–1133PubMedCrossRef
54.
Veldhoen M, Uyttenhove C, van Snick J et al (2008) Transforming growth factor-beta ‘reprograms’ the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat Immunol 9:1341–1346PubMedCrossRef
55.
Trifari S, Kaplan CD, Tran EH, Crellin NK, Spits H (2009) Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol 10:864–871PubMedCrossRef
56.
Ma CS, Deenick EK (2014) Human T follicular helper (Tfh) cells and disease. Immunol Cell Biol 92:64–71PubMedCrossRef
57.
58.
Toda A, Piccirillo CA (2006) Development and function of naturally occurring CD4+CD25+ regulatory T cells. J Leukoc Biol 80:458–470PubMedCrossRef
59.
Chen W, Jin W, Hardegen N et al (2003) Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 198:1875–1886PubMedPubMedCentralCrossRef
60.
Zheng SG, Wang J, Wang P, Gray JD, Horwitz DA (2007) IL-2 is essential for TGF-beta to convert naive CD4+CD25- cells to CD25+Foxp3+ regulatory T cells and for expansion of these cells. J Immunol 178:2018–2027PubMedCrossRef
61.
Mahmud SA, Manlove LS, Farrar MA (2013) Interleukin-2 and STAT5 in regulatory T cell development and function. Jakstat 2, e23154PubMedPubMedCentral
62.
Duhen R, Glatigny S, Arbelaez CA, Blair TC, Oukka M, Bettelli E (2013) Cutting edge: the pathogenicity of IFN-gamma-producing Th17 cells is independent of T-bet. J Immunol 190:4478–4482PubMedPubMedCentralCrossRef
63.
Lochner M, Peduto L, Cherrier M et al (2008) In vivo equilibrium of proinflammatory IL-17+ and regulatory IL-10+ Foxp3+ RORgamma t+ T cells. J Exp Med 205:1381–1393PubMedPubMedCentralCrossRef
64.
Zhou X, Bailey-Bucktrout SL, Jeker LT et al (2009) Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol 10:1000–1007PubMedPubMedCentralCrossRef
65.
66.
67.
O'Shea JJ, Lahesmaa R, Vahedi G, Laurence A, Kanno Y (2011) Genomic views of STAT function in CD4+ T helper cell differentiation. Nat Rev Immunol 11:239–250PubMedPubMedCentralCrossRef
68.
69.
70.
71.
Murray PJ (2007) The JAK-STAT signaling pathway: input and output integration. J Immunol 178:2623–2629PubMedCrossRef
72.
Avery DT, Deenick EK, Ma CS et al (2010) B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans. J Exp Med 207:155–171PubMedPubMedCentralCrossRef
73.
Deenick EK, Avery DT, Chan A et al (2013) Naive and memory human B cells have distinct requirements for STAT3 activation to differentiate into antibody-secreting plasma cells. J Exp Med 210:2739–2753PubMedPubMedCentralCrossRef
74.
75.
Adamkova L, Souckova K, Kovarik J (2007) Transcription protein STAT1: biology and relation to cancer. Folia Biol (Praha) 53:1–6
76.
Szabo SJ, Sullivan BM, Peng SL, Glimcher LH (2003) Molecular mechanisms regulating Th1 immune responses. Annu Rev Immunol 21:713–758PubMedCrossRef
77.
Liu L, Okada S, Kong XF et al (2011) Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med 208:1635–1648PubMedPubMedCentralCrossRef
78.
van de Veerdonk FL, Plantinga TS, Hoischen A et al (2011) STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N Engl J Med 365:54–61PubMedCrossRef
79.
Uzel G, Sampaio EP, Lawrence MG et al (2013) Dominant gain-of-function STAT1 mutations in FOXP3 wild-type immune dysregulation-polyendocrinopathy-enteropathy-X-linked-like syndrome. J Allergy Clin Immunol 131:1611–1623PubMedPubMedCentralCrossRef
80.
Hadj-Slimane R, Chelbi-Alix MK, Tovey MG, Bobe P (2004) An essential role for IFN-alpha in the overexpression of Fas ligand on MRL/lpr lymphocytes and on their spontaneous Fas-mediated cytotoxic potential. J Interferon Cytokine Res 24:717–728PubMedCrossRef
81.
Dong J, Wang QX, Zhou CY, Ma XF, Zhang YC (2007) Activation of the STAT1 signalling pathway in lupus nephritis in MRL/lpr mice. Lupus 16:101–109PubMedCrossRef
82.
Hale MB, Krutzik PO, Samra SS, Crane JM, Nolan GP (2009) Stage dependent aberrant regulation of cytokine-STAT signaling in murine systemic lupus erythematosus. PLoS One 4, e6756PubMedPubMedCentralCrossRef
83.
Reeves WH, Lee PY, Weinstein JS, Satoh M, Lu L (2009) Induction of autoimmunity by pristane and other naturally occurring hydrocarbons. Trends Immunol 30:455–464PubMedPubMedCentralCrossRef
84.
Thibault DL, Chu AD, Graham KL et al (2008) IRF9 and STAT1 are required for IgG autoantibody production and B cell expression of TLR7 in mice. J Clin Invest 118:1417–1426PubMedPubMedCentralCrossRef
85.
Yiu G, Rasmussen TK, Ajami B et al (2015) Development of Th17-associated interstitial kidney inflammation in lupus-prone mice lacking the gene encoding STAT-1. Arthritis Rheumatol
86.
Dominguez-Gutierrez PR, Ceribelli A, Satoh M, Sobel ES, Reeves WH, Chan EK (2014) Positive correlation of STAT1 and miR-146a with anemia in patients with systemic lupus erythematosus. J Clin Immunol 34:171–180PubMedCrossRef
87.
Dominguez-Gutierrez PR, Ceribelli A, Satoh M, Sobel ES, Reeves WH, Chan EK (2014) Elevated signal transducers and activators of transcription 1 correlates with increased C-C motif chemokine ligand 2 and C-X-C motif chemokine 10 levels in peripheral blood of patients with systemic lupus erythematosus. Arthritis Res Ther 16:R20PubMedPubMedCentralCrossRef
88.
Lu MC, Lai NS, Chen HC et al (2013) Decreased microRNA(miR)-145 and increased miR-224 expression in T cells from patients with systemic lupus erythematosus involved in lupus immunopathogenesis. Clin Exp Immunol 171:91–99PubMedCrossRef
89.
Karonitsch T, Feierl E, Steiner CW et al (2009) Activation of the interferon-gamma signaling pathway in systemic lupus erythematosus peripheral blood mononuclear cells. Arthritis Rheum 60:1463–1471PubMedCrossRef
90.
Menon M, Blair PA, Isenberg DA, Mauri C (2016) A regulatory feedback between plasmacytoid dendritic cells and regulatory B cells is aberrant in systemic lupus erythematosus. Immunity 44:683–697PubMedPubMedCentralCrossRef
91.
Huang X, Guo Y, Bao C, Shen N (2011) Multidimensional single cell based STAT phosphorylation profiling identifies a novel biosignature for evaluation of systemic lupus erythematosus activity. PLoS One 6, e21671PubMedPubMedCentralCrossRef
92.
93.
Baechler EC, Batliwalla FM, Karypis G et al (2003) Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 100:2610–2615PubMedPubMedCentralCrossRef
94.
Liang Y, Xu WD, Yang XK et al (2014) Association of signaling transducers and activators of transcription 1 and systemic lupus erythematosus. Autoimmunity 47:141–145PubMedCrossRef
95.
96.
Landolt-Marticorena C, Bonventi G, Lubovich A et al (2009) Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus. Ann Rheum Dis 68:1440–1446PubMedCrossRef
97.
Petri M, Singh S, Tesfasyone H et al (2009) Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus. Lupus 18:980–989PubMedPubMedCentralCrossRef
98.
Gamero AM, Young MR, Mentor-Marcel R et al (2010) STAT2 contributes to promotion of colorectal and skin carcinogenesis. Cancer Prev Res (Phila) 3:495–504CrossRef
99.
Matsumoto M, Tanaka N, Harada H et al (1999) Activation of the transcription factor ISGF3 by interferon-gamma. Biol Chem 380:699–703PubMedCrossRef
100.
Abdul-Sater AA, Majoros A, Plumlee CR et al (2015) Different STAT transcription complexes drive early and delayed responses to type I IFNs. J Immunol 195:210–216PubMedPubMedCentralCrossRef
101.
Hambleton S, Goodbourn S, Young DF et al (2013) STAT2 deficiency and susceptibility to viral illness in humans. Proc Natl Acad Sci U S A 110:3053–3058PubMedPubMedCentralCrossRef
102.
Sriram U, Varghese L, Bennett HL et al (2012) Myeloid dendritic cells from B6.NZM Sle1/Sle2/Sle3 lupus-prone mice express an IFN signature that precedes disease onset. J Immunol 189:80–91PubMedPubMedCentralCrossRef
103.
Ramirez-Velez G, Medina F, Ramirez-Montano L et al (2012) Constitutive phosphorylation of interferon receptor A-associated signaling proteins in systemic lupus erythematosus. PLoS One 7, e41414PubMedPubMedCentralCrossRef
104.
Baccala R, Gonzalez-Quintial R, Schreiber RD, Lawson BR, Kono DH, Theofilopoulos AN (2012) Anti-IFN-α/β receptor antibody treatment ameliorates disease in lupus-predisposed mice. J Immunol 189:5976–5984PubMedPubMedCentralCrossRef
105.
Munroe ME, Lu R, Zhao YD et al (2016) Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification. Ann Rheum Dis. doi:10.​1136/​annrheumdis-2015-208140
106.
Yang XO, Panopoulos AD, Nurieva R et al (2007) STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J Biol Chem 282:9358–9363PubMedCrossRef
107.
Durant L, Watford WT, Ramos HL et al (2010) Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. Immunity 32:605–615PubMedPubMedCentralCrossRef
108.
Harris TJ, Grosso JF, Yen HR et al (2007) Cutting edge: an in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J Immunol 179:4313–4317PubMedCrossRef
109.
Liu X, Lee YS, Yu CR, Egwuagu CE (2008) Loss of STAT3 in CD4+ T cells prevents development of experimental autoimmune diseases. J Immunol 180:6070–6076PubMedPubMedCentralCrossRef
110.
Zhu Y, Zou L, Liu YC (2016) T follicular helper cells, T follicular regulatory cells and autoimmunity. Int Immunol 28:173–179PubMedCrossRef
111.
112.
Liu K, Liang C, Liang Z, Tus K, Wakeland EK (2005) Sle1ab mediates the aberrant activation of STAT3 and Ras-ERK signaling pathways in B lymphocytes. J Immunol 174:1630–1637PubMedCrossRef
113.
Nakou M, Bertsias G, Stagakis I et al (2010) Gene network analysis of bone marrow mononuclear cells reveals activation of multiple kinase pathways in human systemic lupus erythematosus. PLoS One 5, e13351PubMedPubMedCentralCrossRef
114.
Harada T, Kyttaris V, Li Y, Juang YT, Wang Y, Tsokos GC (2007) Increased expression of STAT3 in SLE T cells contributes to enhanced chemokine-mediated cell migration. Autoimmunity 40:1–8PubMedCrossRef
115.
Edwards LJ, Mizui M, Kyttaris V (2015) Signal transducer and activator of transcription (STAT) 3 inhibition delays the onset of lupus nephritis in MRL/lpr mice. Clin Immunol 158:221–230PubMedPubMedCentralCrossRef
116.
Balomenos D, Rumold R, Theofilopoulos AN (1998) Interferon-gamma is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice. J Clin Invest 101:364–371PubMedPubMedCentralCrossRef
117.
Schwarting A, Wada T, Kinoshita K, Tesch G, Kelley VR (1998) IFN-gamma receptor signaling is essential for the initiation, acceleration, and destruction of autoimmune kidney disease in MRL-Fas(lpr) mice. J Immunol 161:494–503PubMed
118.
Haas C, Ryffel B, Le Hir M (1998) IFN-gamma receptor deletion prevents autoantibody production and glomerulonephritis in lupus-prone (NZB x NZW)F1 mice. J Immunol 160:3713–3718PubMed
119.
Ferber IA, Brocke S, Taylor-Edwards C et al (1996) Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J Immunol 156:5–7PubMed
120.
Willenborg DO, Fordham S, Bernard CC, Cowden WB, Ramshaw IA (1996) IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. J Immunol 157:3223–3227PubMed
121.
Chitnis T, Najafian N, Benou C et al (2001) Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis. J Clin Invest 108:739–747PubMedPubMedCentralCrossRef
122.
Singh RR, Saxena V, Zang S et al (2003) Differential contribution of IL-4 and STAT6 vs STAT4 to the development of lupus nephritis. J Immunol 170:4818–4825PubMedPubMedCentralCrossRef
123.
Jacob CO, Zang S, Li L et al (2003) Pivotal role of Stat4 and Stat6 in the pathogenesis of the lupus-like disease in the New Zealand mixed 2328 mice. J Immunol 171:1564–1571PubMedCrossRef
124.
Menke J, Bork T, Kutska B et al (2011) Targeting transcription factor Stat4 uncovers a role for interleukin-18 in the pathogenesis of severe lupus nephritis in mice. Kidney Int 79:452–463PubMedCrossRef
125.
126.
Han JW, Zheng HF, Cui Y et al (2009) Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet 41:1234–1237PubMedCrossRef
127.
Graham RR, Cotsapas C, Davies L et al (2008) Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus. Nat Genet 40:1059–1061PubMedPubMedCentralCrossRef
128.
Harley JB, Alarcon-Riquelme ME, Criswell LA et al (2008) Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet 40:204–210PubMedPubMedCentralCrossRef
129.
Gateva V, Sandling JK, Hom G et al (2009) A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat Genet 41:1228–1233PubMedPubMedCentralCrossRef
130.
131.
Svenungsson E, Gustafsson J, Leonard D et al (2010) A STAT4 risk allele is associated with ischaemic cerebrovascular events and anti-phospholipid antibodies in systemic lupus erythematosus. Ann Rheum Dis 69:834–840PubMedCrossRef
132.
Korman BD, Kastner DL, Gregersen PK, Remmers EF (2008) STAT4: genetics, mechanisms, and implications for autoimmunity. Curr Allergy Asthma Rep 8:398–403PubMedPubMedCentralCrossRef
133.
Namjou B, Sestak AL, Armstrong DL et al (2009) High-density genotyping of STAT4 reveals multiple haplotypic associations with systemic lupus erythematosus in different racial groups. Arthritis Rheum 60:1085–1095PubMedPubMedCentralCrossRef
134.
Lamana A, Lopez-Santalla M, Castillo-Gonzalez R et al (2015) The minor allele of rs7574865 in the STAT4 gene is associated with increased mRNA and protein expression. PLoS One 10, e0142683PubMedPubMedCentralCrossRef
135.
Cho SS, Bacon CM, Sudarshan C et al (1996) Activation of STAT4 by IL-12 and IFN-alpha: evidence for the involvement of ligand-induced tyrosine and serine phosphorylation. J Immunol 157:4781–4789PubMed
136.
Kariuki SN, Kirou KA, MacDermott EJ, Barillas-Arias L, Crow MK, Niewold TB (2009) Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo. J Immunol 182:34–38PubMedPubMedCentralCrossRef
137.
Hellquist A, Jarvinen TM, Koskenmies S et al (2009) Evidence for genetic association and interaction between the TYK2 and IRF5 genes in systemic lupus erythematosus. J Rheumatol 36:1631–1638PubMedCrossRef
138.
Connolly JJ, Hakonarson H (2012) Role of cytokines in systemic lupus erythematosus: recent progress from GWAS and sequencing. J Biomed Biotechnol 2012:798924PubMedPubMedCentralCrossRef
139.
Sigurdsson S, Nordmark G, Garnier S et al (2008) A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5. Hum Mol Genet 17:2868–2876PubMedPubMedCentralCrossRef
140.
Abelson AK, Delgado-Vega AM, Kozyrev SV et al (2009) STAT4 associates with systemic lupus erythematosus through two independent effects that correlate with gene expression and act additively with IRF5 to increase risk. Ann Rheum Dis 68:1746–1753PubMedCrossRef
141.
Lin JX, Leonard WJ (2000) The role of Stat5a and Stat5b in signaling by IL-2 family cytokines. Oncogene 19:2566–2576PubMedCrossRef
142.
Akira S (1999) Functional roles of STAT family proteins: lessons from knockout mice. Stem Cells 17:138–146PubMedCrossRef
143.
Antov A, Yang L, Vig M, Baltimore D, Van Parijs L (2003) Essential role for STAT5 signaling in CD25+CD4+ regulatory T cell homeostasis and the maintenance of self-tolerance. J Immunol 171:3435–3441PubMedCrossRef
144.
Cohen AC, Nadeau KC, Tu W et al (2006) Cutting edge: decreased accumulation and regulatory function of CD4+ CD25(high) T cells in human STAT5b deficiency. J Immunol 177:2770–2774PubMedCrossRef
145.
Piccirillo CA, d'Hennezel E, Sgouroudis E, Yurchenko E (2008) CD4+Foxp3+ regulatory T cells in the control of autoimmunity: in vivo veritas. Curr Opin Immunol 20:655–662PubMedCrossRef
146.
147.
Yang XP, Ghoreschi K, Steward-Tharp SM et al (2011) Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat Immunol 12:247–254PubMedPubMedCentralCrossRef
148.
Hedrich CM, Rauen T, Apostolidis SA et al (2014) Stat3 promotes IL-10 expression in lupus T cells through trans-activation and chromatin remodeling. Proc Natl Acad Sci U S A 111:13457–13462PubMedPubMedCentralCrossRef
149.
Chen Z, Lund R, Aittokallio T, Kosonen M, Nevalainen O, Lahesmaa R (2003) Identification of novel IL-4/Stat6-regulated genes in T lymphocytes. J Immunol 171:3627–3635PubMedCrossRef
150.
Tuomela S, Rautajoki KJ, Moulder R, Nyman TA, Lahesmaa R (2009) Identification of novel Stat6 regulated proteins in IL-4-treated mouse lymphocytes. Proteomics 9:1087–1098PubMedCrossRef
151.
Elo LL, Jarvenpaa H, Tuomela S et al (2010) Genome-wide profiling of interleukin-4 and STAT6 transcription factor regulation of human Th2 cell programming. Immunity 32:852–862PubMedCrossRef
152.
Kaplan MH, Schindler U, Smiley ST, Grusby MJ (1996) Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity 4:313–319PubMedCrossRef
153.
Shimoda K, van Deursen J, Sangster MY et al (1996) Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature 380:630–633PubMedCrossRef
154.
Takeda K, Tanaka T, Shi W et al (1996) Essential role of Stat6 in IL-4 signalling. Nature 380:627–630PubMedCrossRef
155.
156.
Theofilopoulos AN, Koundouris S, Kono DH, Lawson BR (2001) The role of IFN-gamma in systemic lupus erythematosus: a challenge to the Th1/Th2 paradigm in autoimmunity. Arthritis Res 3:136–141PubMedPubMedCentralCrossRef
157.
Luzina IG, Knitzer RH, Atamas SP et al (1999) Vasculitis in the Palmerston North mouse model of lupus: phenotype and cytokine production profile of infiltrating cells. Arthritis Rheum 42:561–568PubMedCrossRef
158.
Nakajima A, Hirose S, Yagita H, Okumura K (1997) Roles of IL-4 and IL-12 in the development of lupus in NZB/W F1 mice. J Immunol 158:1466–1472PubMed
159.
Leng RX, Pan HF, Ye DQ, Xu Y (2012) Potential roles of IL-9 in the pathogenesis of systemic lupus erythematosus. Am J Clin Exp Immunol 1:28–32PubMedPubMedCentral
160.
Ouyang H, Shi Y, Liu Z et al (2013) Increased interleukin 9 and CD4+IL-9+ T cells in patients with systemic lupus erythematosus. Mol Med Rep 7:1031–1037PubMed
161.
Lau M, Tsantikos E, Maxwell MJ, Tarlinton DM, Anderson GP, Hibbs ML (2012) Loss of STAT6 promotes autoimmune disease and atopy on a susceptible genetic background. J Autoimmun 39:388–397PubMedCrossRef
162.
Yu HH, Liu PH, Lin YC et al (2010) Interleukin 4 and STAT6 gene polymorphisms are associated with systemic lupus erythematosus in Chinese patients. Lupus 19:1219–1228PubMedCrossRef
163.
Krutzik PO, Irish JM, Nolan GP, Perez OD (2004) Analysis of protein phosphorylation and cellular signaling events by flow cytometry: techniques and clinical applications. Clin Immunol 110:206–221PubMedCrossRef
164.
Rasmussen TK, Andersen T, Bak RO et al (2015) Overexpression of microRNA-155 increases IL-21 mediated STAT3 signaling and IL-21 production in systemic lupus erythematosus. Arthritis Res Ther 17:154PubMedPubMedCentralCrossRef
165.
Caprioli F, Sarra M, Caruso R et al (2008) Autocrine regulation of IL-21 production in human T lymphocytes. J Immunol 180:1800–1807PubMedCrossRef
166.
Nurieva R, Yang XO, Martinez G et al (2007) Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 448:480–483PubMedCrossRef
167.
Dolff S, Abdulahad WH, Westra J et al (2011) Increase in IL-21 producing T-cells in patients with systemic lupus erythematosus. Arthritis Res Ther 13:157CrossRef
168.
Pratama A, Vinuesa CG (2014) Control of TFH cell numbers: why and how? Immunol Cell Biol 92:40–48PubMedCrossRef
169.
Vinuesa CG, Linterman MA, Goodnow CC, Randall KL (2010) T cells and follicular dendritic cells in germinal center B-cell formation and selection. Immunol Rev 237:72–89PubMedCrossRef
170.
Ettinger R, Kuchen S, Lipsky PE (2008) The role of IL-21 in regulating B-cell function in health and disease. Immunol Rev 223:60–86PubMedCrossRef
171.
Bettelli E, Carrier Y, Gao W et al (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441:235–238PubMedCrossRef
172.
173.
Kluger MA, Melderis S, Nosko A et al (2015) Treg17 cells are programmed by Stat3 to suppress Th17 responses in systemic lupus. Kidney Int 89:158–166CrossRef
174.
Yan D, Farache J, Mathis D, Benoist C (2015) Imbalanced signal transduction in regulatory T cells expressing the transcription factor FoxP3. Proc Natl Acad Sci U S A 112:14942–14947PubMedPubMedCentralCrossRef
175.
Miyara M, Yoshioka Y, Kitoh A et al (2009) Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 30:899–911PubMedCrossRef
176.
Sakaguchi S, Miyara M, Costantino CM, Hafler DA (2010) FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 10:490–500PubMedCrossRef
177.
Kalland ME, Oberprieler NG, Vang T, Tasken K, Torgersen KM (2011) T cell-signaling network analysis reveals distinct differences between CD28 and CD2 costimulation responses in various subsets and in the MAPK pathway between resting and activated regulatory T cells. J Immunol 187:5233–5245PubMedCrossRef
178.
Moulton VR, Tsokos GC (2015) T cell signaling abnormalities contribute to aberrant immune cell function and autoimmunity. J Clin Invest 125:2220–2227PubMedPubMedCentralCrossRef
179.
Golding A, Hasni S, Illei G, Shevach EM (2013) The percentage of FoxP3+Helios+ Treg cells correlates positively with disease activity in systemic lupus erythematosus. Arthritis Rheum 65:2898–2906PubMedPubMedCentralCrossRef
180.
Alexander T, Sattler A, Templin L et al (2013) Foxp3+ Helios+ regulatory T cells are expanded in active systemic lupus erythematosus. Ann Rheum Dis 72:1549–1558PubMedCrossRef
181.
Dupont G, Demaret J, Venet F et al (2014) Comparative dose-responses of recombinant human IL-2 and IL-7 on STAT5 phosphorylation in CD4+FOXP3- cells versus regulatory T cells: a whole blood perspective. Cytokine 69:146–149PubMedCrossRef
182.
Barron L, Dooms H, Hoyer KK et al (2010) Cutting edge: mechanisms of IL-2-dependent maintenance of functional regulatory T cells. J Immunol 185:6426–6430PubMedPubMedCentralCrossRef
183.
184.
Zhang B, Zhang X, Tang FL, Zhu LP, Liu Y, Lipsky PE (2008) Clinical significance of increased CD4+CD25-Foxp3+ T cells in patients with new-onset systemic lupus erythematosus. Ann Rheum Dis 67:1037–1040PubMedCrossRef
185.
Bonelli M, Goschl L, Bluml S et al (2014) CD4(+)CD25(-)Foxp3(+) T cells: a marker for lupus nephritis? Arthritis Res Ther 16:104CrossRef
186.
Flores-Borja F, Bosma A, Ng D et al (2013) CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation. Sci Transl Med 5:173ra123CrossRef
187.
Blair PA, Norena LY, Flores-Borja F et al (2010) CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity 32:129–140PubMedCrossRef
Metadata
Title
The Role of STAT Signaling Pathways in the Pathogenesis of Systemic Lupus Erythematosus
Authors
Aleš Goropevšek
Marija Holcar
Tadej Avčin
Publication date
01-04-2017
Publisher
Springer US
Published in
Clinical Reviews in Allergy & Immunology / Issue 2/2017
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-016-8550-y

Other articles of this Issue 2/2017

Clinical Reviews in Allergy & Immunology 2/2017 Go to the issue

ReviewPaper

CD20-Mimotope Peptide Active Immunotherapy in Systemic Lupus Erythematosus and a Reappraisal of Vaccination Strategies in Rheumatic Diseases

ReviewPaper

Beyond Genetics: What Causes Type 1 Diabetes

ReviewPaper

Epigenetic Variability of CD4+CD25+ Tregs Contributes to the Pathogenesis of Autoimmune Diseases

ReviewPaper

Review of Mouse Models of Graves’ Disease and Orbitopathy—Novel Treatment by Induction of Tolerance

ReviewPaper

An Update on the Use of Immunomodulators in Primary Immunodeficiencies

ReviewPaper

The Clinical Relevance of Anti-DFS70 Autoantibodies
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits